Koen Augustyns

8.4k total citations · 1 hit paper
206 papers, 6.7k citations indexed

About

Koen Augustyns is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Koen Augustyns has authored 206 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Molecular Biology, 86 papers in Oncology and 55 papers in Cellular and Molecular Neuroscience. Recurrent topics in Koen Augustyns's work include Peptidase Inhibition and Analysis (78 papers), Neuropeptides and Animal Physiology (54 papers) and Diabetes Treatment and Management (21 papers). Koen Augustyns is often cited by papers focused on Peptidase Inhibition and Analysis (78 papers), Neuropeptides and Animal Physiology (54 papers) and Diabetes Treatment and Management (21 papers). Koen Augustyns collaborates with scholars based in Belgium, Germany and United Kingdom. Koen Augustyns's co-authors include Pieter Van der Veken, Achiel Haemers, Anne‐Marie Lambeir, Ingrid De Meester, Jurgen Joossens, Simon Scharpé, Kristel Senten, Paul Cos, Peter Vandenabeele and Louis Maes and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Koen Augustyns

203 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors

2023 116 citations Greta Klejborowska, Behrouz Hassannia et al. Trends in Pharmacological Sciences profile →

Peers

Countries citing papers authored by Koen Augustyns

Since Specialization

Citations

This map shows the geographic impact of Koen Augustyns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen Augustyns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen Augustyns more than expected).

Fields of papers citing papers by Koen Augustyns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen Augustyns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen Augustyns. The network helps show where Koen Augustyns may publish in the future.

Co-authorship network of co-authors of Koen Augustyns

This figure shows the co-authorship network connecting the top 25 collaborators of Koen Augustyns. A scholar is included among the top collaborators of Koen Augustyns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koen Augustyns. Koen Augustyns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases 2025 ·Journal of Medicinal Chemistry ·(unknown), Greta Klejborowska, (unknown), Ashley M. Toye, (unknown), Emily Van San, (unknown), Maya Berg, Behrouz Hassannia, Pieter Van der Veken, Hans De Winter, Tom Vanden Berghe, Koen Augustyns	2
2	Human Transmembrane Serine Protease 2 (TMPRSS2) on Human Seminal Fluid Extracellular Vesicles Is Proteolytically Active 2025 ·Journal of Extracellular Vesicles ·(unknown), (unknown), Pascale Berckmans, (unknown), Koen Augustyns, Isabel Pintelon, Maya Berg, Pieter Van Wielendaele, Anne‐Marie Lambeir, Yann G.‐J. Sterckx, Inge Nelissen, Ingrid De Meester	1
3	Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer 2024 ·Nature Communications ·Vincent de Laat, (unknown), Xander Spotbeen, Ali Talebi, Jonas Dehairs, Jakub Idkowiak, Frank Vanderhoydonc, (unknown), (unknown), Maarten Jacquemyn, Michele Wölk, Anna Sablina, Koen Augustyns, Tom Vanden Berghe, Tania Roskams, Dirk Daelemans, Maria Fedorova, Baki Topal, Johannes V. Swinnen	6
4	Active site-directed probes targeting dipeptidyl peptidases 8 and 9 2024 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Sofie Thys, (unknown), (unknown), (unknown), (unknown), Koen Augustyns, Pieter Van Wielendaele, Isabel Pintelon, Ingrid De Meester, (unknown), (unknown)	4
5	Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression 2023 ·Cell Death and Differentiation ·Emily Van San, (unknown), (unknown), Yulia Y. Tyurina, Vladimir A. Tyurin, Hao Zheng, Sze Men Choi, Koen Augustyns, Geert Loo, Bernhard Michalke, Vivek Venkataramani, Shinya Toyokuni, Hülya Bayır, Peter Vandenabeele, Behrouz Hassannia, Tom Vanden Berghe	52
6	The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Greta Klejborowska, Koen Augustyns	21
7	Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors breakdown → 2023 ·Trends in Pharmacological Sciences ·(unknown), Greta Klejborowska, (unknown), Behrouz Hassannia, Tom Vanden Berghe, Koen Augustyns	116
8	Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats 2021 ·Pharmaceutics ·Nikita Hanning, (unknown), Hannah Ceuleers, Tim Boogaerts, Maya Berg, Annemieke Smet, Heiko U. De Schepper, Jurgen Joossens, Alexander L.N. van Nuijs, Joris G. De Man, Koen Augustyns, Ingrid De Meester, Benedicte Y. De Winter	12
9	Lead Optimization of Phthalazinone Phosphodiesterase Inhibitors as Novel Antitrypanosomal Compounds 2020 ·Journal of Medicinal Chemistry ·Irene G. Salado, Abhimanyu K. Singh, (unknown), (unknown), Marco Siderius, Pieter Van der Veken, An Matheeussen, (unknown), (unknown), Sheraz Gul, Louis Maes, (unknown), Rob Leurs, D. Brown, Koen Augustyns	6
10	Efforts towards an On‐Target Version of the Groebke–Blackburn–Bienaymé (GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors 2019 ·Chemistry - A European Journal ·(unknown), (unknown), Dries Van Rompaey, Anne‐Marie Lambeir, Koen Augustyns, Hans De Winter, Pieter Van der Veken	12
11	Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome 2018 ·British Journal of Pharmacology ·Hannah Ceuleers, Nikita Hanning, (unknown), (unknown), Jurgen Joossens, Pieter Van der Veken, Sven Francque, (unknown), Anne‐Marie Lambeir, Joris G. De Man, Jean‐Pierre Timmermans, Koen Augustyns, Ingrid De Meester, Benedicte Y. De Winter	36
12	Regulation of intestinal permeability: The role of proteases 2017 ·World Journal of Gastroenterology ·(unknown), Hannah Ceuleers, (unknown), (unknown), Jurgen Joossens, Koen Augustyns, Anne‐Marie Lambeir, Ingrid De Meester, Joris G. De Man, Benedicte Y. De Winter	139
13	Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay 2016 ·European Journal of Medicinal Chemistry ·(unknown), Mandy O. J. Grootaert, (unknown), (unknown), Ria Roelandt, Jurgen Joossens, Anne‐Marie Lambeir, Guido R.Y. De Meyer, Wim Declercq, Koen Augustyns, Wim Martinet, Pieter Van der Veken	12
14	In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain 2014 ·Nuclear Medicine and Biology ·Leonie Wyffels, David Thomae, Ann‐Marie Waldron, (unknown), Stefanie Dedeurwaerdere, Pieter Van der Veken, Jurgen Joossens, Sigrid Stroobants, Koen Augustyns, Steven Staelens	31
15	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries 2011 ·Biological Chemistry ·Veerle Matheeussen, Lesley Baerts, Guido R.Y. De Meyer, Gilles W. De Keulenaer, Pieter Van der Veken, Koen Augustyns, Véronique Dubois, Simon Scharpé, Ingrid De Meester	59
16	Prolyl oligopeptidase stimulates the aggregation of α-synuclein 2008 ·Peptides ·Inger Brandt, Melanie Gérard, Kjell Sergeant, Bart Devreese, Veerle Baekelandt, Koen Augustyns, Simon Scharpé, Yves Engelborghs, Anne‐Marie Lambeir	76
17	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: Isoindoline containing inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Pieter Van der Veken, Véronique Dubois, (unknown), Anne‐Marie Lambeir, Xin Chen, Achiel Haemers, Simon Scharpé, Ingrid De Meester, Koen Augustyns	62
18	Dipeptidyl α-fluorovinyl Michael acceptors: Synthesis and activity against cysteine proteases 2007 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Ibrahim El Tantawy El Sayed, Pieter Van der Veken, Alisa Krishtal, Christian Van Alsenoy, Gareth D. Westrop, Jeremy C. Mottram, Graham H. Coombs, Koen Augustyns, Achiel Haemers	29
19	Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes 2003 ·Expert Opinion on Therapeutic Patents ·Koen Augustyns, Pieter Van der Veken, Kristel Senten, Achiel Haemers	52
20	Trypanothione as a Target in the Design of Antitrypanosomal and Antileishmanial Agents 2001 ·Current Pharmaceutical Design ·Koen Augustyns, Katie Amssoms, Abdellah Yamani, Padinchare Rajan, Achiel Haemers	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact